Related Experiment Video
Updated: Sep 3, 2025
09:13
Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
Published on: April 6, 2017
12.1K
Colchicine as a Modulator of Platelet Function: A Systematic Review
Caroline J Reddel1, Gabrielle J Pennings1, Vivien M Chen1,2
1ANZAC Research Institute, University of Sydney, Concord Repatriation General Hospital, Sydney, Australia.
Seminars in Thrombosis and Hemostasis
|July 26, 2022
Summary
Colchicine, an anti-inflammatory drug, impacts platelet function, potentially contributing to its cardiovascular benefits. Further clinical research is needed to confirm these effects on platelet biology in vivo.
Area of Science:
- Cardiovascular Pharmacology
- Hematology
- Inflammation Research
Background:
- Colchicine is an anti-inflammatory agent used for conditions involving inflammasome activation.
- It is known to prevent coronary and cerebrovascular events.
- Previous studies suggest colchicine directly affects platelets, but this area needs current investigation.
Purpose of the Study:
- To critically review the effects of colchicine on platelet biology.
- To assess both in vitro and in vivo data on colchicine's impact on platelets.
Main Methods:
- Systematic review of Embase, Medline, and PubMed databases.
- Included studies tested platelets after colchicine incubation or reported clinical effects on platelet function.
- Excluded reviews and conference abstracts; focused on English-language papers.
Main Results:
- Colchicine inhibits platelet aggregation, clotting, degranulation, and extracellular vesicle formation in vitro, often at supraphysiological concentrations.
- Physiological colchicine concentrations inhibit collagen- and calcium ionophore-induced platelet aggregation and signaling.
- Limited in vivo studies exist regarding colchicine's effects on platelets.
Conclusions:
- The interaction between colchicine and platelets may contribute to its cardiovascular protective effects.
- High-quality clinical research is urgently needed to validate the in vivo impact of colchicine on platelet function.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
625
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
625
01:10Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
01:18Structure and Function of Platelets
1.5K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
1.5K
01:27Peripheral Artery Disease III: Interprofessional Care
28
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
28
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
871
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
871
01:22Formation of the Platelet Plug
7.0K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
7.0K